CARsgen Therapeutics and Huadong Medicine (Hangzhou) will collaborate on the commercialisation of CARsgen’s BCMA CAR-T product CT053 in mainland China.
CT053 (zevorcabtagene autoleucel, Zevor-cel) is CARsgen’s lead drug candidate and an autologous CAR T-cell product treating relapsed/refractory multiple myeloma (R/R MM).
Dr Zonghai Li, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics Holdings Limited, said: “Despite advancements in recent years, there are still significant unmet medical needs for the treatment of multiple myeloma. Zevor-cel, a differentiated BCMA CAR T cell therapy, has shown promising data in clinical programs and is now under NDA priority review by NMPA.
“We believe this collaboration with Huadong Medicine will enhance the successful commercialisation of zevor-cel in mainland China.”
Under the terms of the agreement, CARsgen will receive an upfront payment of RMB200 million and is eligible to receive regulatory and commercial milestone payments up to RMB1,025 million.
CARsgen will continue to be responsible for the development, regulatory approval, and manufacturing of CT053 in mainland China.
Liang Lv, Chairman of Huadong Medicine, added: “We are excited to collaborate with CARsgen to commercialise CT053. Huadong is committed to bringing CT053, an innovative and highly effective new treatment, to more R/R MM patients in China, and improve their survival and quality of life.”
